{"id":37360,"date":"2025-07-15T17:35:04","date_gmt":"2025-07-15T09:35:04","guid":{"rendered":"https:\/\/flcube.com\/?p=37360"},"modified":"2025-07-15T17:35:05","modified_gmt":"2025-07-15T09:35:05","slug":"golden-age-health-secures-exclusive-rights-to-innostellars-gene-therapy-lx-101-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37360","title":{"rendered":"Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China"},"content":{"rendered":"\n

Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar’s first-in-class gene therapy candidate LX-101 in Mainland China.<\/p>\n\n\n\n

LX-101: A Novel Gene Therapy for Inherited Retinal Dystrophy<\/strong>
LX-101 is an adeno-associated virus (AAV)-based gene therapy designed to deliver functional RPE65 genes directly to retinal cells. The primary goal of this therapy is to restore the visual cycle in patients with inherited retinal dystrophy (IRD) caused by biallelic RPE65 mutations. This innovative approach aims to address a significant unmet medical need in the treatment of IRD.<\/p>\n\n\n\n

Clinical Development and Regulatory Pathway<\/strong>
LX-101 is currently undergoing a Phase III clinical study in China. Topline results from this study are anticipated in the fourth quarter of 2025. Following these results, Innostellar plans to submit a marketing authorization application to China’s National Medical Products Administration (NMPA).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has…<\/p>\n","protected":false},"author":1,"featured_media":37364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[66,4221,4222,24],"class_list":["post-37360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-gene-therapy","tag-golden-age-health","tag-innostellar-biotherapeutics","tag-rare-orphan-disease-drugs"],"yoast_head":"\nGolden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar's first-in-class gene therapy candidate LX-101 in Mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37360\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China\" \/>\n<meta property=\"og:description\" content=\"Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar's first-in-class gene therapy candidate LX-101 in Mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37360\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T09:35:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T09:35:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China\",\"datePublished\":\"2025-07-15T09:35:04+00:00\",\"dateModified\":\"2025-07-15T09:35:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360\"},\"wordCount\":183,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1512.webp\",\"keywords\":[\"Gene therapy\",\"Golden Age Health\",\"Innostellar Biotherapeutics\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37360#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37360\",\"name\":\"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1512.webp\",\"datePublished\":\"2025-07-15T09:35:04+00:00\",\"dateModified\":\"2025-07-15T09:35:05+00:00\",\"description\":\"Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar's first-in-class gene therapy candidate LX-101 in Mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37360\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1512.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1512.webp\",\"width\":1080,\"height\":608,\"caption\":\"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37360#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China - Insight, China's Pharmaceutical Industry","description":"Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar's first-in-class gene therapy candidate LX-101 in Mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37360","og_locale":"en_US","og_type":"article","og_title":"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China","og_description":"Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar's first-in-class gene therapy candidate LX-101 in Mainland China.","og_url":"https:\/\/flcube.com\/?p=37360","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-15T09:35:04+00:00","article_modified_time":"2025-07-15T09:35:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37360#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37360"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China","datePublished":"2025-07-15T09:35:04+00:00","dateModified":"2025-07-15T09:35:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37360"},"wordCount":183,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37360#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp","keywords":["Gene therapy","Golden Age Health","Innostellar Biotherapeutics","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37360#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37360","url":"https:\/\/flcube.com\/?p=37360","name":"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37360#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37360#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp","datePublished":"2025-07-15T09:35:04+00:00","dateModified":"2025-07-15T09:35:05+00:00","description":"Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has entered into a 10-year exclusive promotion service agreement with China-headquartered Innostellar Biotherapeutics Co., Ltd. This strategic partnership secures the exclusive commercialization and promotion rights to Innostellar's first-in-class gene therapy candidate LX-101 in Mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37360#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37360"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37360#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp","width":1080,"height":608,"caption":"Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37360#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1512.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37360"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37360\/revisions"}],"predecessor-version":[{"id":37365,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37360\/revisions\/37365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37364"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}